{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines LRRK2 kinase activity as a disease mechanism in PD and links its inhibition to therapeutic potential."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Binding and enzymatic assays were used to assess ATP affinity and kinase activity of LRRK2 mutants.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays and ATP binding studies are standard in LRRK2 research and directly model the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wild-type LRRK2 was used as a control. Assays were performed in triplicate.",
              "judgment": "Yes",
              "reasoning": "Wild-type controls and triplicate experiments satisfy basic validity requirements."
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "No known pathogenic/benign variants were explicitly used as controls for I2020T or G2019S.",
              "judgment": "No",
              "reasoning": "The study lacks direct comparisons to established pathogenic/benign variants for these mutants.",
              "next_step_or_outcome": "Max PS3_supporting/BS3_supporting"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "Fold changes in ATP affinity and kinase activity were reported (e.g., 2-fold lower, 6-fold higher). No explicit OddsPath calculations.",
              "judgment": "No",
              "reasoning": "Lack of OddsPath or detailed statistical metrics limits quantitative interpretation."
            },
            {
              "step_name": "Sub-step 4b: No OddsPath Calculation",
              "extracted_paper_info": "Only two variants (I2020T and G2019S) were analyzed as controls in this study.",
              "judgment": "Yes",
              "reasoning": "Fewer than 11 control variants were used, so evidence strength remains Max PS3_supporting/BS3_supporting."
            }
          ]
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines LRRK2 kinase activity as a disease mechanism in PD and links its inhibition to therapeutic potential."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Binding and enzymatic assays were used to assess ATP affinity and kinase activity of LRRK2 mutants.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays and ATP binding studies are standard in LRRK2 research and directly model the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wild-type LRRK2 was used as a control. Assays were performed in triplicate.",
              "judgment": "Yes",
              "reasoning": "Wild-type controls and triplicate experiments satisfy basic validity requirements."
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "No known pathogenic/benign variants were explicitly used as controls for I2020T or G2019S.",
              "judgment": "No",
              "reasoning": "The study lacks direct comparisons to established pathogenic/benign variants for these mutants.",
              "next_step_or_outcome": "Max PS3_supporting/BS3_supporting"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "Fold changes in ATP affinity and kinase activity were reported (e.g., 2-fold lower, 6-fold higher). No explicit OddsPath calculations.",
              "judgment": "No",
              "reasoning": "Lack of OddsPath or detailed statistical metrics limits quantitative interpretation."
            },
            {
              "step_name": "Sub-step 4b: No OddsPath Calculation",
              "extracted_paper_info": "Only two variants (I2020T and G2019S) were analyzed as controls in this study.",
              "judgment": "Yes",
              "reasoning": "Fewer than 11 control variants were used, so evidence strength remains Max PS3_supporting/BS3_supporting."
            }
          ]
        }
      ],
      "final_strength": "PS3_supporting"
    }
  ]
}